3P

3i Plc

Description

Global Private Equity

Investor Profile

3i Plc has made 2 investments, with 0 in the past 12 months and 50% as lead.

Stage Focus

  • Series Unknown (50%)
  • Series A (50%)

Country Focus

  • United Kingdom (50%)
  • Germany (50%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Neuroscience
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does 3i Plc frequently co-invest with?

Abingworth
Europe, England, United Kingdom, London
Co-Investments: 1
Credit Suisse First Boston
Europe, Zurich, Switzerland, Zurich
Co-Investments: 1
Star Ventures
Europe, Bayern, Germany, München
Co-Investments: 1
Pacific Rim Ventures
North America, California, United States, San Francisco
Co-Investments: 1
MVM Life Science Partners
Europe, England, United Kingdom, London
Co-Investments: 1
Invesco
North America, Georgia, United States, Atlanta
Co-Investments: 1
QF
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 1
OppenheimerFunds
North America, Georgia, United States, Peachtree City
Co-Investments: 1
Schroder Ventures
Europe, England, United Kingdom, London
Co-Investments: 1

What are some of recent deals done by 3i Plc?

Evotec Neurosciences

Hamburg, Hamburg, Germany

Evotec Neurosciences GmbH engages in the discovery and development of small molecule drugs.

BiopharmaBiotechnologyHealth CareNeuroscience
Series AApr 2, 2004
Amount Raised: $30,465,847
Oxagen

London, England, United Kingdom

Oxagen is a biopharmaceutical company developing small molecule drugs addressing asthma, and chronic allergic and inflammatory conditions.

BiopharmaBiotechnologyHealth CarePharmaceutical
Series UnknownDec 21, 2000
Amount Raised: $44,240,218